Literature DB >> 11555443

Post-kala-azar dermal leishmaniasis: does it play a role in the transmission of Leishmania donovani in the Sudan?

A M El Hassan1, E A Khalil.   

Abstract

In 1997 a sudden outbreak of visceral leishmaniasis (VL) occurred in eastern Sudan, coinciding with an increase of post-kala-azar dermal leishmaniasis (PKDL) cases which may in part be because of sylvatic and anthroponotic transmission. Paradoxically, the more VL patients are treated, the higher the frequency of PKDL. If PKDL plays a role in transmission, its treatment would be expected to reduce infection in the area. Treatment of PKDL, however, requires four times the amount of Pentostam used for treating VL, and the drug is both expensive and in short supply.

Entities:  

Mesh:

Year:  2001        PMID: 11555443     DOI: 10.1046/j.1365-3156.2001.00776.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  12 in total

1.  Leishmania promastigote membrane antigen-based enzyme-linked immunosorbent assay and immunoblotting for differential diagnosis of Indian post-kala-azar dermal leishmaniasis.

Authors:  Samiran Saha; Tuhina Mazumdar; Khairul Anam; Rajesh Ravindran; Bibhas Bairagi; Bibhuti Saha; Ramapada Goswami; Netai Pramanik; Subhashis K Guha; Sourjya Kar; Dwijadas Banerjee; Nahid Ali
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

2.  Post-kala-azar dermal leishmaniasis in Nepal: a retrospective cohort study (2000-2010).

Authors:  Surendra Uranw; Bart Ostyn; Arpana Rijal; Saru Devkota; Basudha Khanal; Joris Menten; Marleen Boelaert; Suman Rijal
Journal:  PLoS Negl Trop Dis       Date:  2011-12-20

3.  Post-Kala-Azar Dermal Leishmaniasis: A Paradigm of Paradoxical Immune Reconstitution Syndrome in Non-HIV/AIDS Patients.

Authors:  Eltahir Awad Gasim Khalil; Selma Abdelmoneim Khidir; Ahmed Mudawi Musa; Brema Younis Musa; Mona Elfaki Eltahir Elfaki; Abdelgadir Mohamed Yousif Elkadaru; Edward Zijlstra; Ahmed Mohamed El-Hassan
Journal:  J Trop Med       Date:  2013-03-24

4.  Treatment-based strategy for the management of post-kala-azar dermal leishmaniasis patients in the Sudan.

Authors:  A M Musa; E A G Khalil; B M Younis; M E E Elfaki; M Y Elamin; A O A Adam; H A A Mohamed; M M M Dafalla; A A Abuzaid; A M El-Hassan
Journal:  J Trop Med       Date:  2013-04-15

5.  Microalbuminuria and glomerular filtration rate in paediatric visceral leishmaniasis.

Authors:  Neena Verma; Chandra Shekhar Lal; Vidyanand Rabidas; Krishna Pandey; Dharmendra Singh; Sanjay Kumar; Rakesh Bihari Verma; Pradeep Das
Journal:  Biomed Res Int       Date:  2013-06-23       Impact factor: 3.411

6.  Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis.

Authors:  Hashim Ghalib; Farrokh Modabber
Journal:  Kinetoplastid Biol Dis       Date:  2007-08-17

7.  Report of the Post Kala-azar Dermal Leishmaniasis (PKDL) Consortium Meeting, New Delhi, India, 27-29 June 2012.

Authors:  Philippe Desjeux; Raj Shankar Ghosh; Pritu Dhalaria; Nathalie Strub-Wourgaft; Ed E Zijlstra
Journal:  Parasit Vectors       Date:  2013-07-02       Impact factor: 3.876

8.  Concomitant Infection with Leishmania donovani and L. major in Single Ulcers of Cutaneous Leishmaniasis Patients from Sudan.

Authors:  A M Babiker; S Ravagnan; A Fusaro; M M Hassan; S M Bakheit; M M Mukhtar; G Cattoli; G Capelli
Journal:  J Trop Med       Date:  2014-03-12

9.  A Comparison of the Effectiveness of Sodium Stibogluconate Monotherapy to Sodium Stibogluconate and Paromomycin Combination for the Treatment of Severe Post Kala Azar Dermal Leishmaniasis in South Sudan - A Retrospective Cohort Study.

Authors:  Charles Abongomera; Francis Gatluak; Jozefine Buyze; Koert Ritmeijer
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

Review 10.  A review of visceral leishmaniasis during the conflict in South Sudan and the consequences for East African countries.

Authors:  Waleed Al-Salem; Jennifer R Herricks; Peter J Hotez
Journal:  Parasit Vectors       Date:  2016-08-22       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.